SCHEMBL26199837

SCHEMBL26199837

CCOC(=O)C(CO)NC(=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP26A1 O43174 1/20 0.53
SMN1; SMN2 Q16637 4/20 0.51
CTSL P07711 1/20 0.51
RAB9A P51151 3/20 0.50
NPC1 O15118 2/20 0.50
GAA P10253 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ALDH1A1 P00352 1/20 0.48
PRSS1 P07477 1/20 0.47
CTSG P08311 1/20 0.47
CTRB1 P17538 1/20 0.47
CMA1 P23946 1/20 0.47
P2RY12 Q9H244 1/20 0.46
GPR139 Q6DWJ6 1/20 0.46
BCHE P06276 2/20 0.46
ACHE P22303 2/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27673425 1.00 CYP26A1 (0.53) CYP26A1SMN1; SMN2CTSLRAB9ANPC1
SCHEMBL29188972 0.89 CYP26A1 (0.54) CYP26A1SMN1; SMN2CTSLRAB9ANPC1
SCHEMBL12985221 0.88 MEN1 (0.50) CYP26A1SMN1; SMN2RAB9AGAAMEN1
SCHEMBL12985219 0.88 MEN1 (0.50) CYP26A1SMN1; SMN2RAB9AGAAMEN1
SCHEMBL5672076 0.87 GAA (0.56) CYP26A1CTSLRAB9AGAAKMT2A
SCHEMBL10024019 0.87 GAA (0.56) CYP26A1CTSLRAB9AGAAKMT2A
SCHEMBL4896298 0.86 NPC1 (0.53) CYP26A1SMN1; SMN2CTSLRAB9ANPC1
SCHEMBL7443637 0.86 CYP26A1 (0.52) CYP26A1SMN1; SMN2CTSLRAB9ANPC1
SCHEMBL7443638 0.86 CYP26A1 (0.52) CYP26A1SMN1; SMN2CTSLRAB9ANPC1
SCHEMBL839816 0.85 CTSL (0.59) CYP26A1CTSLTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074887-A1 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF Sea Pharmaceuticals LLC. (US) 2025-03-06 US disclosed
WO-2023130008-A2 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF SEA PHARMACEUTICALS LLC (US) 2023-07-06 WO disclosed
CN-88102858-A Process for preparing hydrazine derivatives useful as antihypertensive agents 1988-12-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074887-A1 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF GABRQ, GRIK5, CYP3A7 CYP26A1 62/4885SMN1; SMN2 1334/4885CTSL 1719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.